Copyright ©ERS Journals Ltd 2008 Keratinocyte growth factor prevents intra-alveolar oedema in experimental lung isografts1 Laboratory of Experimental Surgery, Dept of General and Thoracic Surgery, 2 Dept of Internal Medicine, University of Giessen Lung Center, Justus-Liebig-University Giessen, Giessen, 3 Clinical Research Group "Chronic Airway Diseases", Clinic of Internal Medicine (Respiratory Medicine), Philipps University of Marburg, Marburg, and 4 Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany. 5 These authors contributed equally to the study. CORRESPONDENCE: V. Grau, Laboratory of Experimental Surgery, Dept of General and Thoracic Surgery, University of Giessen Lung Center, Justus-Liebig-University Giessen, Rudolf-Buchheim-Str. 7, D-35385 Giessen, Germany. Fax: 49 6419944709. E-mail: Veronika.Grau{at}chiru.med.uni-giessen.de Keywords: Keratinocyte growth factor, lung, oedema, primary graft dysfunction, transplantation
Received: January 31, 2007
Primary graft dysfunction, characterised by intra-alveolar oedema, is a major obstacle in pulmonary transplantation. The present study evaluates the potential of keratinocyte growth factor (palmiferin;
Intratracheal instillation of 5 mg·kg–1
In grafts from control treated donors, the fraction of intra-alveolar oedema amounted to 3.4±1.1% of the total parenchymal volume. Treatment of donor lungs with
Treatment of donor lungs with palifermin protects against intra-alveolar oedema formation upon transplantation. This effect appears to be mediated by an improved surfactant homeostasis.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||